StemRIM
Notice of Registration of Use Patent for Cartilage Disease Treatment in Israel
A use patent related to Ledasemotide for the treatment of cartilage diseases is scheduled to be registered in Israel. There is no impact on full-year results for the fiscal year ending July 2027. If disclosure-worthy matters arise, they will be announced separately.
Key Figures
- Patent filing region: Israel
- Applicants: StemRIM, Osaka University (National University Corporation Osaka University)
- Title of invention: Treatment for cartilage diseases
AI要約
Key Points of the News
Announced that a use patent for a cartilage disease treatment related to regenerative induction drug Ledasemotide is scheduled to be registered in Israel. Applicants are StemRIM and Osaka University. This is part of efforts to expand indications currently under development.
Financial Impact and Future
The patent registration is stated to have no impact on full-year results for the fiscal year ending July 2027. The company will promptly disclose if disclosure-worthy matters arise; the timing of any actual impact from patent acquisition and new business opportunities is unknown.
StemRIM
Company overview · Stock price · Financial data · All IR
